Raymond James Initiates Coverage On Legend Biotech with Outperform Rating, Announces Price Target of $86
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Sean McCutcheon initiates coverage on Legend Biotech (NASDAQ:LEGN) with an Outperform rating and a price target of $86.
March 13, 2024 | 8:45 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Raymond James initiated coverage on Legend Biotech with an Outperform rating and a price target of $86, indicating a positive outlook.
The initiation of coverage by a reputable analyst with an Outperform rating and a high price target suggests a strong bullish sentiment towards Legend Biotech. This is likely to positively influence investor perception and could lead to an increase in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100